Comparative Pharmacology
Head-to-head clinical analysis: PURIXAN versus THIOGUANINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PURIXAN versus THIOGUANINE.
PURIXAN vs THIOGUANINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Purixan (mercaptopurine) is a purine analog that inhibits de novo purine synthesis by interfering with nucleotide interconversion and incorporation into DNA and RNA. It requires intracellular activation to 6-mercaptopurine ribonucleotide (6-MP ribonucleotide) via hypoxanthine-guanine phosphoribosyltransferase (HGPRT).
Thioguanine is a purine analog that incorporates into DNA and RNA, inhibiting purine nucleotide synthesis and cell replication. It acts as an antimetabolite, specifically targeting S-phase of the cell cycle.
75 mg/kg once weekly orally; may be increased by 25 mg/kg every 2-4 weeks to a maximum of 150 mg/kg once weekly.
2 mg/kg orally once daily for 4 weeks, then 2 mg/kg orally every other day; or 2-3 mg/kg/day orally for 5 days per cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged to 20-50 hours in renal impairment. Clinically, monitoring for myelosuppression is essential due to accumulation.
Terminal half-life approximately 11 hours (range 5-16 hours) in adults; extends to 20-30 hours in renal impairment.
Renal excretion of unchanged drug and metabolites; approximately 50% as unchanged drug, 20% as 6-thiouric acid, and minor amounts as other metabolites. Biliary/fecal elimination accounts for less than 10%.
Primarily renal; 40% excreted unchanged in urine within 24 hours; minor biliary/fecal elimination (<10%).
Category C
Category D/X
Antimetabolite
Antimetabolite